Caitlyn Stromko
About Caitlyn Stromko
Caitlyn Stromko is a Clinical Scientist at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in clinical research and regulatory documentation.
Current Position at Bristol Myers Squibb
Caitlyn Stromko is currently employed at Bristol Myers Squibb in Princeton, New Jersey, United States, where she serves as a Clinical Scientist. Her role involves developing key study documents, including protocols, ICFs, CRFs, amendments, and training materials. She also collaborates with cross-functional teams and external partners while adhering to FDA regulations and ICH/GCP guidelines.
Previous Roles at Bristol Myers Squibb
Before becoming a Clinical Scientist, Caitlyn Stromko held several positions at Bristol Myers Squibb. She was a Research Scientist I (Jan 2019 - Oct 2019), an Associate Research Scientist II (2017 - 2019), an Associate Research Scientist I (2016 - 2017), and a Contract Pharmacology Technician (2015 - 2016). In these roles, she gained extensive experience in preclinical in vivo immuno-oncology, ADME/PK research, and clinical development operations.
Work Experience at XenoBiotic Laboratories, Inc.
Caitlyn Stromko also worked at XenoBiotic Laboratories, Inc., a subsidiary of WuXi AppTec, Inc. She served as an Associate Scientist II for six months in 2015 and as an Associate Scientist I from 2013 to 2015. During her tenure, she was involved in valuable research and development activities, contributing to the company's scientific mission.
Educational Background
Caitlyn Stromko received her Master's degree from Drexel University, where she studied from 2017 to 2021. She also earned a Bachelor of Science (BS) degree from York College of Pennsylvania, studying from 2010 to 2013. Additionally, she attended Mercer County Community College from 2008 to 2009. Her academic foundation is in biological sciences and has equipped her with critical skills for her professional roles.
Research and Specialization
Caitlyn specializes in late-phase clinical trials focusing on hepatocellular carcinoma, as well as preclinical in vivo immuno-oncology and ADME/PK research. She monitors and analyzes clinical data, identifies trends, and prepares responses for investigators and regulatory bodies. Her expertise extends to submitting clinical contributions to regulatory documents and overseeing clinical research operations.